CNTX earnings: real EPS beat/miss history, analyst consensus Buy, P/E -1.45. Updated 2026-07-23.
Context Therapeutics (CNTX) Research Hub
Context Therapeutics (CNTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.3504 USD (-5.30%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.45, market cap 0.06B. This hub links to the full technical, earnings and options research available for CNTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.3504 USD (-5.30%) |
| 52-week range | 0.3436 USD – 1.3 USD |
| Trend regime | Range |
| 14-day RSI | 28.9 (Oversold) |
| Trailing P/E | -1.45 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
Available research for CNTX
Covered Call on CNTX: how it works, illustrative setup around the real 0.3504 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CNTX: how it works, illustrative setup around the real 0.3504 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CNTX: how it works, illustrative setup around the real 0.3504 USD price, max profit/loss, breakeven and when to use it. Educational.
CNTX technical analysis: range, last 0.3504 USD, RSI 28.9, 52w range 0.3436 USD–1.3 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CNTX in?
Context Therapeutics (CNTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CNTX in an uptrend or downtrend?
As of 2026-09-11, CNTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CNTX's trailing P/E ratio?
CNTX's trailing P/E is -1.45, with a market cap of 0.06B. See the earnings research page for full valuation detail.